• Blog
  • News
  • All services
  • EN
  • EN
  • +34 91 277 10 76
  • info@azierta.com
logo
  • Azierta
    • About Us
    • Meet Our Team
    • Contact us
  • Services
    • Pharmacovigilance
      • ICSR Management
      • EudraVigilance Registration & Support
      • XEVMPD, Art. 57
      • Safety Reports
      • Signal Detection
      • QPPV support
      • Pharmacovigilance Quality system
      • PSMF and Pharmacovigilance agreements
      • Vigilazierta: Safety database
    • Regulatory Affairs
      • Products registration
      • Dossiers compilation
      • Post-authorization support
      • IDMP – Identification of Medicinal Products
    • GxP Compliance & Safety
      • Toxicological Evaluation of Impurities and Risk Analysis
      • Toxicology reports
      • Biosafety Support
      • REACH Compliance Support- CLP
      • GxP Support: Advice & Implementation of Quality Systems
      • ISO Compliance Support
      • Medical Cannabis Consultancy
    • Digital, Science & Growth
      • Digital Strategy
      • Content Marketing
      • Software Solutions
      • Data & Analytics
    • Audit & Certification
      • GxP Audits
      • Supplier Audit Reports
      • Clinical Analysis Laboratories Audits
      • Audits for Compliance of Medical Devices
      • Medical Cannabis Audits
      • Data Integrity Audits
      • Internal Audits
    • Azierta Care
      • Cosmetics
      • Food Supplements
      • Medical Devices
    • Strategy & Intelligence
      • Life Science Investment Consulting
      • Life Science Business Development
      • Next Generation Regulatory Intelligence
      • Translational Medicine and Clinical Development
      • Next-generation Medical Affairs
  • Integrated Programs
    • Animal Health
    • Biopharma
    • Quality Management System
    • Landing in Europe
    • Medical Cannabis
    • Replace Titanium dioxide
    • Vigilazierta: Safety Database
  • Careers
    • Azierta Associates
  • Academy
  • Contact Us
  • e-Consulting
e-Consulting
logo
logo

EU

  • Home  
  • EU
business
Azierta
  • January 15, 2020
  • /
  • By azierta
  • /
  • 0 Comments

Accessing the EU Market: Becoming a suitable CMO for Europe (III)

Pharmaceutical companies are faced with the need to outsource the manufacturing processes of their products for a variety of reasons and are directing their resources towards marketing, rather than production and drug discovery. In recent years, the volume of generic drug sales has been increasing rapidly in Europe, whereas the outsourcing of branded pharmaceuticals has been growing at […]

READ MORE

Search

Categories

  • All
  • Animal Health
  • Audit & Certification
  • Azierta
  • Cannabis
  • Cosmetics
  • Food Supplements
  • GxP Compliance & Safety
  • Landing in Europe
  • Medical Devices
  • News
  • Pharmacovigilance
  • Quality
  • Regulatory Affairs
  • Toxicology

Latest posts

  • Main Changes revision ICH Q3D (R2) on elemental impurities guideline
  • Azierta has attended Food 4 Future 2022
  • Inorganic impurities
  • Azierta attending at Vitafoods Europe
  • Azierta Care and the importance of diversifying markets
Get back to home
© 2021 Azierta Contract Science Support Consulting, All Rights Reserved.